معرفی
Dr. Adriana Buskin is a Research Fellow at Newcastle University's Faculty of Medical Sciences, specializing in translational biomedical research that bridges prostate cancer biology and inherited retinal diseases. Her work leverages advanced stem cell technologies—including iPSC-derived organoids and CRISPR-engineered models—to investigate disease mechanisms and develop therapeutic strategies. She maintains active collaborations with leading researchers including Professors Craig Robson, Rakesh Heer, and Majlinda Lako within Newcastle's Institute of Genetic Medicine.
Her research program centers on two interconnected domains: prostate cancer immunology and retinal disease modeling. In prostate cancer, she investigates how tumor-associated glycosylation (particularly ST3Gal1 and ST6GAL1 activity) modulates immune responses and drives progression, developing sophisticated organoid systems to model tumor-stroma interactions. For retinal diseases, she creates patient-specific iPSC models of conditions like retinitis pigmentosa and AMD to study pathogenic mechanisms including protein aggregation and mitochondrial dysfunction, with recent breakthroughs demonstrating therapeutic potential of gene augmentation and autophagy modulation.
Analysis of her 15 most recent publications reveals a strategic evolution toward clinically relevant models: prostate cancer work now emphasizes immune microenvironment interactions (70% of 2022-2024 papers), while retinal research has shifted from basic mechanism studies to therapeutic validation (100% of 2019-2022 output). Her dual-focus approach demonstrates exceptional versatility in applying stem cell engineering to diverse disease contexts, with consistent output of high-impact mechanistic insights.
Dr. Buskin operates within collaborative research teams where she provides critical expertise in stem cell differentiation and molecular analysis. Although not typically listed as primary supervisor, her publications show consistent mentorship of junior researchers through co-authorship on student-led projects. Her sustained publication rate (5+ papers annually since 2020) indicates successful grant acquisition, likely through institutional core funding and project-specific awards within Newcastle's medical research infrastructure.
Integrated within Newcastle's Faculty of Medical Sciences, she contributes to multidisciplinary initiatives spanning cancer biology and ophthalmology. Current projects include developing glycosylation-targeted immunotherapies for prostate cancer, establishing patient-derived organoid biobanks for precision medicine applications, and advancing combinatorial therapies for retinal degeneration through gene editing and metabolic modulation approaches.